| Title |
Topical Rapamycin Therapy to Alleviate the Cutaneous Manifestations of Tuberous Sclerosis Complex
|
|---|---|
| Published in |
Drugs in R&D, December 2012
|
| DOI | 10.2165/11634580-000000000-00000 |
| Pubmed ID | |
| Authors |
Mary Kay Koenig, Adelaide A. Hebert, Joan Roberson, Joshua Samuels, John Slopis, Audrey Woerner, Hope Northrup |
| Abstract |
Facial angiofibromas are disfiguring facial lesions, present in up to 80% of patients with tuberous sclerosis complex. Recent elucidation of the complex cell signaling pathways that are disrupted in tuberous sclerosis indicates that rapamycin may be successful in alleviating the appearance of these lesions. The objectives of the current study were to evaluate the safety of topically applied rapamycin in patients with tuberous sclerosis complex and to determine its potential effectiveness in treatment of facial angiofibromas. |
Mendeley readers
The data shown below were compiled from readership statistics for 72 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 1% |
| Netherlands | 1 | 1% |
| United States | 1 | 1% |
| Unknown | 69 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 10 | 14% |
| Student > Bachelor | 7 | 10% |
| Researcher | 6 | 8% |
| Student > Master | 6 | 8% |
| Student > Ph. D. Student | 5 | 7% |
| Other | 16 | 22% |
| Unknown | 22 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 27 | 38% |
| Nursing and Health Professions | 5 | 7% |
| Agricultural and Biological Sciences | 4 | 6% |
| Biochemistry, Genetics and Molecular Biology | 2 | 3% |
| Mathematics | 1 | 1% |
| Other | 6 | 8% |
| Unknown | 27 | 38% |
Attention Score in Context
This research output has an Altmetric Attention Score of 14. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 February 2018.
All research outputs
#2,233,939
of 22,710,079 outputs
Outputs from Drugs in R&D
#33
of 330 outputs
Outputs of similar age
#23,209
of 280,104 outputs
Outputs of similar age from Drugs in R&D
#5
of 29 outputs
Altmetric has tracked 22,710,079 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 330 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 280,104 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 29 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 82% of its contemporaries.